Abstracts
3427182
(#44) Mobile Measurement-Based Care for Symptom Monitoring in Patients Undergoing Pharmacogenomic (PGx) Testing
Abstract: Background: Patients with psychiatric illnesses face inconsistent responses to medication. Pharmacogenomic (PGx) testing can identify patients at higher risk of medication side effects and inefficient treatment response, while mobile health apps enable measurement-based care (MBC) to track side effect burden and symptom severity longitudinally. This study evaluates the potential impact of PGx testing on patient outcomes and engagement as measured by mobile MBC.
Methods: We analyzed 2,593 de-identified records from a real-world database (Tempus AI, Inc.) to compare side effect burden and symptom severity before and after PGx testing. We used Wilcoxon signed-rank tests to evaluate changes between initial and final assessment scores. We also quantified patient engagement between those who received PGx testing and those who did not.
Results: The cohort was predominantly female (73%), with depression (62%) and anxiety (58%) as the most common diagnoses. Abnormal variants in the genes CYP2C19, CYP2D6, HTR2A, or SLC6A4 were observed in 89% of patients. Following PGx testing, we observed mean reductions in patient-reported side effect burden (FIBSER, -29%), depression severity (PHQ-9, -22%), and anxiety severity (GAD-7, -22%), all p 0.001. Importantly, patients who received a PGx report demonstrated higher participation in mobile-based assessments compared to those who did not (mean 3.5 assessments completed vs. 2.7).
Conclusion: A majority of patients harbor a genomic variant that may impact medication efficacy or tolerability. Integrating PGx testing with digital MBC is associated with significant symptom reduction, decreased side effect burden, and increased patient participation in clinical tracking.
Short Description: This study of 2,593 patients demonstrates that integrating pharmacogenomic (PGx) testing with mobile measurement-based care potentially improves psychiatric outcomes. Following PGx testing, patients showed a reduction in side effect burden and depression/anxiety symptoms. Furthermore, patients receiving PGx results exhibited higher engagement with digital health tracking compared to those without testing. These findings suggest that personalized genomic insights combined with mobile monitoring can effectively optimize individual treatment response and overall clinical participation.
Name of Sponsoring Organization(s): Tempus, AI.
Methods: We analyzed 2,593 de-identified records from a real-world database (Tempus AI, Inc.) to compare side effect burden and symptom severity before and after PGx testing. We used Wilcoxon signed-rank tests to evaluate changes between initial and final assessment scores. We also quantified patient engagement between those who received PGx testing and those who did not.
Results: The cohort was predominantly female (73%), with depression (62%) and anxiety (58%) as the most common diagnoses. Abnormal variants in the genes CYP2C19, CYP2D6, HTR2A, or SLC6A4 were observed in 89% of patients. Following PGx testing, we observed mean reductions in patient-reported side effect burden (FIBSER, -29%), depression severity (PHQ-9, -22%), and anxiety severity (GAD-7, -22%), all p 0.001. Importantly, patients who received a PGx report demonstrated higher participation in mobile-based assessments compared to those who did not (mean 3.5 assessments completed vs. 2.7).
Conclusion: A majority of patients harbor a genomic variant that may impact medication efficacy or tolerability. Integrating PGx testing with digital MBC is associated with significant symptom reduction, decreased side effect burden, and increased patient participation in clinical tracking.
Short Description: This study of 2,593 patients demonstrates that integrating pharmacogenomic (PGx) testing with mobile measurement-based care potentially improves psychiatric outcomes. Following PGx testing, patients showed a reduction in side effect burden and depression/anxiety symptoms. Furthermore, patients receiving PGx results exhibited higher engagement with digital health tracking compared to those without testing. These findings suggest that personalized genomic insights combined with mobile monitoring can effectively optimize individual treatment response and overall clinical participation.
Name of Sponsoring Organization(s): Tempus, AI.
